Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 8/20 | 0.43 |
| ▸ | CASP3 | P42574 | 4/20 | 0.42 |
| ▸ | IL1B | P01584 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.31 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 3/20 | 0.31 |
| ▸ | GZMB | P10144 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10251411 | 1.00 | CASP1 (0.43) | CASP1CASP3IL1BELANEITGB1 | |
| SCHEMBL10247759 | 0.84 | CASP1 (0.42) | CASP1IL1BELANECTSS | |
| SCHEMBL10199404 | 0.84 | CASP1 (0.42) | CASP1IL1BELANECTSS | |
| SCHEMBL13637689 | 0.84 | CASP1 (0.42) | CASP1CASP3IL1BCASP8GZMB | |
| SCHEMBL647407 | 0.80 | CASP1 (0.44) | CASP1CASP3IL1BCASP8 | |
| SCHEMBL645919 | 0.80 | CASP1 (0.44) | CASP1CASP3IL1BCASP8 | |
| SCHEMBL10199551 | 0.80 | CASP1 (0.46) | CASP1CASP3IL1BCASP8 | |
| SCHEMBL10248117 | 0.80 | CASP1 (0.46) | CASP1CASP3IL1BCASP8 | |
| SCHEMBL10200732 | 0.80 | CASP1 (0.47) | CASP1CASP3IL1BCASP8 | |
| SCHEMBL10199406 | 0.79 | CASP1 (0.46) | CASP1CASP3IL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CASP1 6/4885CASP3 85/4885IL1B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.